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Abstract
Background: Despite recent changes to expand the ART eligibility criteria in sub-Saharan Africa, many patients still initiate
ART in the advanced stages of HIV infection, which contributes to increased early mortality rates, poor patient outcomes,
and onward transmission.
Methods: To evaluate individual and clinic-level factors associated with late ART initiation in Mozambique, we conducted a
retrospective sex-specific analysis of data from 36,411 adult patients who started ART between January 2005 and June 2009
at 25 HIV clinics in Mozambique. Late ART initiation was defined as CD4 count,100 cells/mL or WHO stage IV. Mixed effects
models were used to identify patient- and clinic-level factors associated with late ART initiation.
Results: The proportion of patients initiating ART late decreased from 46% to 37% during 2005–2007, but remained
constant (between 37–33%) from 2007–2009. Of those who initiated ART late (median CD4=57 cells/mL), 5% were known to
have died and 54% were lost to clinic within 6 months of ART initiation (compared with 2% and 47% among other patients
starting ART [median CD4=192 cells/mL]). In multivariate analysis, female sex and pregnancy at ART initiation
(AORfemale_not_pregnant_vs._male=0.66, 95%CI [0.62–0.69]; AORpregnant_vs._non_pregnant=0.60, 95%CI [0.49–0.73]), younger and
older age (AOR15–25_vs.26–30=0.86, 95%CI [0.79–0.94], AOR.45_vs.26–30=0.72, 95%CI [0.67–0.77]), entry into care via PMTCT
(AORentry_through_PMTCT_vs.VCT=0.42, 95%CI [0.35–0.50]), marital status (AORmarried/in union_vs.single=0.87, 95%CI [0.83–0.92]),
education (AORsecondary_or_higher_vs.primary=0.87, 95%CI [0.83–0.93]) and year of ART initiation were associated with a lower
likelihood of late ART initiation. Clinic-level factors independently associated with a lower likelihood of late ART initiation
included CD4 machine on-site (AORCD4_machine_onsite_vs.offsite=0.83, 95%CI [0.74–0.94]) and presence of PMTCT services
onsite (AOR=0.85, 95%CI [0.77–0.93]).
Conclusion:: The risk of starting ART late remained persistently high. Efforts are needed to ensure identification and
enrollment of patients at earlier stages of HIV disease. Individual and clinic level factors identified may provide clues for
upstream structural interventions.
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Introduction
In 2009, Sub-Saharan Africa was home to 68% of the
estimated 33.3 million people living with HIV/AIDS worldwide
[1]. Since 2004, there has been a rapid increase in antiretroviral
therapy (ART) coverage in this region and approximately 37% of
HIV-infected patients in need of treatment in sub-Saharan Africa
had access to it in 2009 based on the criteria in the 2006 WHO
guidelines [1]. Among the most important challenges to
maximizing the impact of HIV care and treatment program
outcomes are high rates of late ART initiation (i.e., initiation of
ART in the advanced stages of HIV disease) [2–5], which in turn
is associated with both high rates of mortality soon after initiation
of ART (early mortality) and onward HIV transmission [6,7].
Even though mortality in HIV-infected patients has decreased
substantially with the scale-up of ART [6], mortality of patients
starting ART in resource-limited settings has been shown to be
substantially higher than in industrialized countries, especially in
the first year following ART initiation [8]. In sub-Saharan
Africa, one review article reported between 8 and 26% of
patients die within 12 months after starting ART, with most
deaths occurring in the first few months [6]. This high early
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[9]. In fact, data from ART programs in 12 sub-Saharan
countries found that most patients continue to start ART with
CD4 counts well below the recommended threshold [10]. A
cross-sectional study from a clinic in rural Uganda observed that
40% of the 2,311 patients initiating ART had WHO stage IV
and found that male sex, lower education level and unemploy-
ment, among other factors, were associated with a higher
likelihood of late ART initiation [11]. Identifying those factors
associated with late ART initiation is critical to inform strategies
to address this issue.
With an estimated national HIV prevalence of 11.5% in 2009
[12], Mozambique has experienced a rapid scale-up of HIV care
and treatment programs, with the number of people on ART
increasing from less than 2,000 in 2003 to more than 190,000 by
July 2010 [13,14]. Despite this accomplishment, it is estimated
that only 37% of those in need of ART in Mozambique have
initiated treatment [15]. A retrospective study looking at follow-
up outcomes of 154,188 patients enrolled in 28 clinics between
2003 and 2009 in Mozambique observed low CD4 at ART
initiation and high mortality rates [16]. Additionally, a study
conducted in Zambezia province found that among those ART
eligible at enrollment (21%), only 58% initiated ART within 90
days of enrollment, and older age and higher level of education
were strongly predictive of ART initiation [17]. The objective of
this analysis is to determine the extent of late ART initiation
among adults across a large number of HIV care and treatment
programs in Mozambique and identify patient and clinic-level
factors associated with late ART initiation to help inform the
development of upstream structural intervention.
Methods
Ethics Statement
This study was part of the Identifying Optimal Models of HIV
Care and Treatment in Mozambique Collaboration and
Multilevel Determinants of Late ART Initiation (LSTART)
Study, which was approved by the Mozambican National Ethics
Committee and the Columbia University Medical Center IRB.
Additional technical and administrative approval was received
from the US Centers for Disease Control and Prevention and the
Office of the Global AIDS Coordinator (OGAC), US Depart-
ment of State. Patients were not asked for informed consent to
participate given that this study is solely based on secondary data
analysis from de-identified routine service delivery data. Both as
part of LSTART and the Optimal Models Collaboration, the
Columbia University IRB Committee did not consider this study
to be human subjects research as there was no interaction with
subjects, there was no intervention and private, identifiable
information was not being collected.
Study population and ART eligibility
The study population included patients aged $15 who started
ART from January 1, 2005 through June 30, 2009 at 25 HIV care
and treatment clinics. All clinics were part of the national HIV
care and treatment program in Mozambique and were located in
urban and rural locations within five different provinces: Maputo,
Gaza, Inhambane, Nampula and Zambezia (Figure 1). These HIV
clinics were receiving direct support from ICAP- Columbia
University through funding via PEPFAR.
During the study period, the Mozambican national guidelines
(2006 & 2008) specified the following eligibility criteria for ART
initiation: 1) WHO stage IV disease, 2) WHO stage III and CD4
count ,350 cell/mL or 3) CD4 count ,200 cells/mL, irrespective
of WHO stage [18]. Since 2006, Mozambican guidelines further
specified that all HIV-infected patients should have a compre-
hensive medical history taken, receive a physical examination and
an appropriate laboratory assessment at their first HIV care visit to
determine, among other things, ART eligibility. For patients who
were not yet ART eligible, the guidelines specified a semiannual
visit schedule with clinical and CD4+ cell count monitoring.
Patients found to be ART eligible are required to attend three
ART readiness counseling sessions and disclose their HIV status to
a treatment partner (ie, parent, spouse, relative, friend). After this,
the patient could be re-evaluated to confirm ART eligibility and
readiness prior to prescription of ART. For patients with
CD4,350 cells/mL or clinical WHO stage 3 or 4, cotrimoxazole
was indicated.
Outcome definition
Among those who initiated ART during the study period,
patients for whom WHO staging or CD4 cell count values were
available are included in the analysis. Late ART initiation was
defined as having a CD4 count,100 cells/mL or WHO stage IV
at any time prior to ART initiation or up to one month after ART
initiation.
Patient characteristics
Patient information routinely collected during each clinic visit
was documented by clinicians on national patient forms included
in patient charts. Trained data clerks routinely abstracted relevant
data for baseline and all follow-up clinic visits from patient charts
into an electronic database including: sex, age, weight, and WHO
disease stages and CD4+ cell counts. Other variables included:
pregnancy status at ART initiation, age, marital status, years of
schooling, socio-economic status), source of referral (e.g., voluntary
counseling and testing [VCT] service, TB clinic, prevention of
mother-to-child transmission [PMTCT] program) and year of
ART initiation. Loss to follow-up (LTF) was defined as not having
had a clinic or pharmacy visit during the last 6 months of the study
period (ie, Jan–Jun 2009).
Clinic characteristics
Information on clinic and program characteristics was derived
from annual structured site assessments completed by ICAP field
staff at each clinic. These assessments captured information
regarding: the type of setting (urban, rural), the type of facility
(primary, secondary, tertiary), year the facility began providing
ART, laboratory services (e.g., availability of CD4 testing),
presence of patient support services (e.g. peer educators or
outreach for patients who miss clinic visits) and presence of
programmatic services (e.g. prevention of mother to child
transmission program). Rounds of clinic assessments were
conducted in June 2007, December 2007, July 2008 and July
2009, and linked to data on patients initiating ART during these
time periods. Data from the June 2007 site assessment was used as
a proxy for clinic characteristics prior to 2007.
Statistical Analysis
Statistical analyses were carried out using SAS version 9.2 (SAS
Institute, Cary, NC). Mixed effects models were used to identify
patient- and clinic-level factors associated with late ART initiation
using the GLIMMIX procedure in SAS. Variables significant at
the 0.20 level in the univariate analysis were included in the
multivariate analysis and, using a backward stepwise procedure,
retained if significant at the 0.05 level based on the likelihood ratio
test. Because the factors associated with late ART initiation likely
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analyses were conducted to evaluate the impact of missing data in
the final results.
Results
Study population
Between January 2005 and June 2009, 40,995 adult patients
started ART at the 25 clinics, which represented an estimated
31.0% of all patients that had ever started ART in Mozambique
by June 2009 [19]. Of those, 4,584 (11%) patients did not have a
WHO stage or CD4 cell count to be classified as late or non-late
ART initiators and were excluded from the main analysis (but
examined under various assumptions in sensitivity analyses). The
proportion of patients with missing WHO stage and CD4 count
was greatest in 2005 (22%) but stabilized around 10% in the
following years. Of the remaining 36,411 patients included in the
main analysis, 27,784 patients (76%) had CD4 cell counts
available at ART initiation and their median CD4 cell count was
150 cells/mL [interquartile range (IQR) 72–219] and 30,675
patients had WHO stage available at ART initiation (15% with
WHO stage IV). A total of 14,010 (38%) of the 36,411 included
in main analysis initiated ART late (WHO stage 4 and/or CD4
count ,100 cells/mL), including 44% of men, 36% of non-
pregnant women and 17% of pregnant women. Of the 14,010
patients who initiated ART late, 76% had a CD4 count,100
cells/mL, 34% had a WHO stage 4 and 10% had both at ART
initiation.
Figure 1. Geographic distribution of the 25 sites included in this analysis.
doi:10.1371/journal.pone.0037125.g001
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Characteristics of the patients included are presented in Table 1.
More than half were women (60%) and 852/16,361 (3.8%) were
documented as being pregnant at ART initiation. The median age
at ART initiation was 35.0 years (IQR 28.6–43.0), the median for
women was 33.0 years (IQR 27.2–40.4) and for men 38.0 years
(IQR 31.1–45.4). Among those with information on marital status,
56% of the patients were married or in union. Despite statistically
significant differences in the distribution of patient-level charac-
teristics between late and non-late initiators, only gender and
calendar year of ART initiation had substantial differences in the
distribution between both groups. Among those that initiated
ART late (median CD4=57 cells/mL [IQR,25–89]), 5% were
known to have died within 6 months and 54% were LTF; while
among other patients initiating ART it was 2% and 47%,
respectively (median CD4=192 cells/mL [IQR,151–255]). The
proportion initiating ART late remained relatively constant
(between 37–33%) from 2007 through the first half of 2009.
Clinic characteristics
Of the 25 clinics included in the analysis, 21 (84%) were located
in urban settings and 4 (16%) were located in rural settings, with
7.8% of the patients coming from rural clinics (Table 2). All were
public sector facilities with 11 primary facilities, 9 secondary and 5
tertiary facilities. CD4+ cell count testing was available onsite in
14(56%) of the facilities, with these clinics contributing the
majority (71%) of the patients included in this analysis. Nineteen
clinics (76%) reported having an outreach program for patients
who missed clinic visits, seventeen of which were dedicated only
for ART patients, while only two focused on all patients (pre-ART
or ART) who missed visits. Finally, 21% (84%) had peer educators
available and 21 (84%) had PMTCT services available on-site.
Factors associated with late ART initiation
The results of the univariate and multivariate analyses for all
patients, females, and males are shown in Appendix S1 and
Table 3, respectively. In the multivariate analysis, non-pregnant
women were significantly less likely than men to initiate ART late
(AOR=0.66, 95%CI [0.62–0.69]) as were pregnant women
(AOR=0.60, 95%CI [0.49–0.73]) when compared to non-
pregnant women. Older patients (.45 years old) in the overall
group had lower odds of late ART initiation (AOR=0.72, 95%CI
[0.67–0.77]), as did older women (AOR=0.74, 95%CI [0.68–
0.82]) and older men (AOR=0.66, 95%CI [0.59–0.74]). Overall
patients that entered care through inpatient settings had higher
odds of late ART initiation than those entering through VCT
(AOR=1.4, 95%CI [1.3–1.6]). Among women, those entering
care through PMTCT services were significantly less likely to
initiate ART late than those entering via VCT (AOR=0.42,
95%CI [0.35–0.50]). Patients that were married or in union and
those widowed had lower odds of late ART initiation compared to
those that were single in the overall group (AOR=0.87, 95%CI
[0.83–0.92], AOR=0.87,95% CI [0.83–0.92], respectively) and
among women (married/in union AOR=0.79,95%CI[0.74–
0.85], widowed AOR=0.85,95%CI[0.77–0.94]). Compared with
having less education, having a secondary education or higher was
associated with a lower odds of late ART initiation among all
patients (AOR=0.87, 95%CI [0.83–0.93]), and among men and
women separately. Compared to those patients starting ART in
2005, those who initiated in more recent calendar years had lower
odds of being late ART initiators but it stabilized after 2007.
Clinic-level factors that were independently associated with late
ART initiation among all patients included availability of CD4 cell
count testing onsite versus offsite (AOR=0.83, 95%CI [0.74–
0.94]) and onsite versus offsite availability of PMTCT services
(AOR=0.85, 95%CI [0.77–0.93]). In the multivariate model for
women, onsite availability of CD4 cell count testing (AOR=0.86,
95%CI [0.75–0.98]) and PMTCT services (AOR=0.81, 95%CI
[0.72–0.91]) were significantly associated with lower odds of late
ART initiation. Finally, men initiating ART at rural clinics
(AORrural_vs._urban=0.73, 95%CI [0.54–0.99]) and clinics with
onsite CD4 cell count testing (AOR=0.83, 95%CI [0.54–0.99])
were significantly less likely to initiate ART late. Sites with peer
education programs were significantly associated with a lower
likelihood of late ART initiation in univariate analysis (Table 3).
However, peer educator programs were no longer significant after
controlling for other patient and program-level factors, and having
a more recent year of ART initiation appeared to explain most of
the relationship between peer education and late ART initiation.
Sensitivity analysis
In order to evaluate the impact of missing data on the outcome
of late ART initiation on our main findings, sensitivity analyses
were conducted with the 4,584 patients that had been excluded
from the main analysis due to missing information on WHO stage
and/or CD4 cell count at ART initiation. The proportion of
patients with late ART initiation among all patients who initiate
ART ranged from 34%, if those with missing WHO stage or CD4
cell count at ART initiation are assumed to not have initiated
ART late, to 45%, if all those with these missing data are classified
as having initiated ART late. Excluded patients were incorporated
in multivariate model and treated as late ART initiators in one
model and as non-late ART initiators in a second model. When we
compared these models to that in Table 3, the findings were not
materially altered.
Discussion
Our study found a median CD4 cell count at ART initiation of
150 cells/mL among patients who initiated ART at 25 HIV care
and treatment clinics in Mozambique. A high proportion of
patients (38%, range across sites: 21%–52%) started ART late
(CD4,100 or WHO IV) and of these, 5% were known to have
died and 54% were lost to clinic within 6 months of ART
initiation. These data are consistent with several other studies in
the sub-Saharan African region [3,4,6,8–11,16,20–29]. Our study
identified several individual- and clinic-level factors that were
independently associated with late ART initiation, some of which
are modifiable and can thus be utilized to inform upstream,
structural interventions aimed at promoting more timely ART
initiation.
A number of individual-level factors were found to be
independently associated with a lower likelihood of late ART
initiation, including female sex, pregnancy at ART initiation, entry
into care via a PMTCT program, younger (15–25 years) and older
age (.40 years), more years of education and being married or
widowed (among females only). In sub-Saharan Africa, women on
average initiate ART at an earlier stage of HIV-disease than men
[28,30]. One likely reason is the expansion of HIV testing for
pregnant women in antenatal care through PMTCT programs
leading to identification of HIV among asymptomatic women
[31,32]. Some approaches to reach men earlier include promotion
of HIV testing in general among populations with high HIV
prevalence, support to workplace HIV testing programs [33,34] as
well as to promote HIV testing among household members of
HIV-infected individuals [35–37]. In fact, even though pediatric
children were not the included in this analysis, late HIV diagnosis
in adults in Mozambique are a serious problem in the late
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association with younger age and lower risk of late ART initiation
seems plausible since younger age is likely associated with both a
shorter duration of HIV infection and higher testing rates in most
sub-Saharan African countries [39–44]. The association with older
age and lower risk of late ART initiation is consistent with what
has recently been described in rural Mozambique [17]. Among
women, being widowed or married/in union was associated with
lower risk of late ART initiation when compared to those who
were single. The death of a spouse could prompt an individual to
seek an HIV test prior to the onset of symptoms, especially if HIV
is suspected as a possible cause death in the spouse, and further
Table 1. Patient-level characteristics at ART initiation.
a
Characteristics Total Late ART initiators Non-late ART initiators
(N=36,411) (N=14,010) (N=22,401) p-value
N( % ) n( % ) n( % )
Sex
Male 13,731 37.7 6,117 43.7 7,614 34.0 ,0.001
Female (not pregnant at ART initiation) 21,828 59.9 7,752 55.3 14,076 62.8
Female (pregnant at ART initiation) 852 2.3 141 1.0 711 3.2
Age (years)
15–25 3,920 10.8 1,322 9.4 2,598 11.6 ,0.001
26–30 6,871 18.9 2,693 19.2 4,178 18.7
31–35 7,452 20.5 2,951 21.1 4,501 20.1
35–40 5,983 16.4 2,450 17.5 3,533 15.8
41–45 4,755 13.1 1,930 13.8 2,825 12.6
.45 7,430 20.4 2,664 19.0 4,766 21.3
Point of entry
VCT 12,077 33.2 4,650 33.2 7,427 33.2 ,0.001
PMTCT 1,308 3.6 202 1.4 1,106 4.9
TB/HIV 308 0.8 129 0.9 179 0.8
Inpatient 1,802 4.9 868 6.2 934 4.2
Outpatients 2,066 5.7 828 5.9 1,238 5.5
Other
b 16,015 44.0 6,118 43.7 9,897 44.2
Missing 2,835 7.8 1,215 8.7 1,620 7.2
Marital status
Single 10,789 29.6 4,299 30.7 6,490 29.0 ,0.001
Married/In union 17,181 47.2 6,397 45.7 10,784 48.1
Widowed 2,913 8.0 1,021 7.3 1,892 8.4
Missing 5,528 15.2 2,293 16.4 3,235 14.4
Years of schooling
None/very low (#3 years) 1,733 4.8 676 4.8 1,057 4.7 0.009
Primary school (4–8 years) 17,603 48.3 6,737 48.1 10,866 48.5
Secondary school or higher (.8 years) 8,216 22.6 3,069 21.9 5,147 23.0
Missing 8,859 24.3 3,528 25.2 5,331 23.8
Socio-economic status
Higher 12,020 33.0 4,623 33.0 7,397 33.0 0.041
Lower 22,651 62.2 8,668 61.9 13,983 62.4
Missing 1,740 4.8 719 5.1 1,021 4.6
Calendar year of ART initiation
2005 2,970 8.2 1,376 9.8 1,594 7.1 ,0.001
2006 7,132 19.6 3,186 22.7 3,946 17.6
2007 10,579 29.1 3,953 28.2 6,626 29.6
2008 10,172 27.9 3,645 26.0 6,527 29.1
First half 2009 5,558 15.3 1,850 13.2 3,708 16.6
aIncludes only individuals with available data.
bIncludes referrals from other health facilities, youth centers, private clinics, laboratory, and emergency room.
doi:10.1371/journal.pone.0037125.t001
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infection. There are other factors that we were not able to assess
that have been previously described as barriers for retention in
care and early ART initiation, including distance and cost of
transportation to clinic, work responsibilities, family commitments
or cumbersome ART initiation procedures [17,39].
The risk of late ART initiation between 2005 and 2007
decreased from 46% to 37%. This may reflect the effect of rapidly
increasing ART coverage [40], more efficient triaging of the
sickest patients, and increasing HIV testing uptake among HIV-
infected persons in Mozambique. However, the proportion of
patients initiating late in our sample changed only slightly from
2007 through the first half of 2009. This leveling off is concerning
and community and clinic level interventions that focus on earlier
diagnosis and enrollment into care are urgently needed [5]. In sub-
Saharan Africa, HIV testing uptake is variable [41–52], but
generally low throughout the region (e.g., in 2008 only 22% of
people 15–49 years old knew their HIV status [40]), despite the
availability of ART. As testing and ART coverage increase, rates
of late ART initiation would be expected to further decrease.
However, the plateau in our data suggests a suboptimal steady
state may have been reached in the catchment areas of these 25
clinics.
A number of clinic-level factors were found to be independently
associated with late ART initiation. Male patients enrolled at rural
clinics and clinics were less likely to initiate ART late (consisting
with a prior investigation [4], although men in rural sites
represented only 8% of the men included in this analysis.
Availability of CD4+ cell count testing onsite (as opposed to
offsite) was associated with a lower risk of late ART initiation in
both females and males. This might reflect ease of obtaining such
tests and the ability of the clinicians to more closely monitor CD4+
cell count results and determine ART eligibility in a timely
manner. It could also reflect other unmeasured factors related to
the clinic maturity and capacity to provide a higher quality of pre-
ART care. A substantial proportion of clinics in our analysis did
not have CD4 testing available onsite (52%) and 29% of patients
in this analysis were recruited at such clinics. The availability of
cost-effective point of care CD4 analyzers could facilitate the use
of such assays at smaller clinics enabling better monitoring of pre-
ART patients and allowing for timely initiation of ART once
eligible [53]. Women initiating ART at clinics that also had an on-
site PMTCT program were significantly less likely to initiate ART
late, independently of whether individual women entered the
program via PMTCT. This may reflect ease of referral of HIV-
Table 2. Clinic and program characteristics of sites where patients started ART stratified by sex.
Total no. sites Total Late ART initiators Non-late ART initiators
(N=25) (N=36,411) (N=14,010) (N=22,401) p-value
n (%) N (%) n (%) n (%)
Setting
Urban 21 84.0 33,401 91.7 13,208 94.3 20,437 91.2 ,0.001
Rural 4 16.0 3,010 8.3 802 5.7 1,964 8.8
Type of facility
Primary 11 44.0 7,418 20.4 2,607 18.6 4,811 21.5 ,0.001
Secondary 9 36.0 19,016 52.2 7,255 51.8 11,761 52.5
Tertiary 5 20.0 9,977 27.4 4,148 29.6 5,829 26.0
Year the facility began providing ART
Before 2005 5 20.0 11,607 31.9 4,864 34.7 6,743 30.1 ,0.001
2005 7 28.0 11,770 32.3 4,364 31.1 7,406 33.1
2006 10 40.0 10,591 29.1 4,001 28.6 6,590 29.4
2007 2 8.0 1,629 4.5 553 3.9 1,076 4.8
2008 1 4.0 814 2.2 228 1.6 586 2.6
CD4 testing
On-site 14 56.0 26,160 71.8 10,252 73.2 15,908 71.0 ,0.001
Off-site 11 44.0 10,251 28.2 3,758 26.8 6,493 29.0
Outreach program targeted to
All patients 2 8.0 11,500 31.6 4,584 32.7 6,916 30.9 ,0.001
Only ART patients 17 68.0 14,021 38.5 5,199 37.1 8,822 39.4
None 6 24.0 10,890 29.9 4,227 30.2 6,663 29.7
Peer education service
Yes 21 84.0 17,791 48.9 6,533 46.6 11,258 50.3 ,0.001
No 4 16.0 18,620 51.1 7,477 53.4 11,143 49.7
Availability PMTCT services
On-site 21 84.0 23,587 64.8 8,726 62.3 14,861 66.3 ,0.001
Off-site 4 16.0 12,824 35.2 5,284 37.7 7,540 33.7
doi:10.1371/journal.pone.0037125.t002
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a
Characteristics Overall AOR Women AOR Men AOR
(95%CI) (95%CI) (95%CI)
(N=36,411) (N=22,680) (N=13,731)
Patient-level characteristics
Sex
Male 1
Female (not pregnant at ART initiation) 0.66 (0.62–0.69) 1- -
Female (pregnant at ART initiation) 0.38 (0.31–0.47) 0.60 (0.49–0.73) --
Age (years)
15–25 0.86 (0.79–0.94) 0.90 (0.81–0.99) 0.72 (0.61–0.87)
26–30 1 1 1
31–35 0.96 (0.89–1.0) 0.96 (0.89–1.0) 0.93 (0.83–1.0)
35–40 0.97 (0.90–1.0) 0.96 (0.88–1.1) 0.94 (0.84–1.1)
41–45 0.91 (0.84–0.99) 0.88 (0.79–0.97) 0.92 (0.81–1.0)
.45 0.72 (0.67–0.77) 0.74 (0.68–0.82) 0.66 (0.59–0.74)
Point of entry
VCT 1 1 1
PMTCT 0.42 (0.35–0.50) 0.42 (0.35–0.50) 0.69 (0.36–1.3)
TB/HIV 1.2 (0.98–1.6) 1.4 (1.0–2.0) 1.1 (0.79–1.5)
Inpatient 1.4 (1.3–1.6) 1.5 (1.3–1.7) 1.3 (1.1–1.5)
Outpatients 0.97 (0.86–1.1) 1.1 (0.94–1.3) 0.84 (0.70–0.99)
Other
b 1.0 (0.86–1.1) 1.0 (0.94–1.3) 0.88 (0.79–0.97)
Missing 1.1 (0.97–1.2) 1.1 (0.99–1.3) 1.0 (0.83–1.1)
Marital status
Single 1 1 - -
Married/In union 0.87 (0.83–0.92) 0.79 (0.74–0.85) --
Widowed 0.87 (0.83–0.92) 0.85 (0.77–0.94) --
Missing 0.92 (0.84–1.0) 0.93 (0.83–1.0) - -
Years of schooling
None/very low (#3 years) 1.1 (0.99–1.2) 1.1 (0.93–1.2) 1.2 (0.99–1.6)
Primary school (4–8 years) 1 1 1
Secondary school or higher (.8 years) 0.87 (0.83–0.93) 0.85 (0.79–0.92) 0.89 (0.82–0.97)
Missing 1.0 (0.95–1.1) 1.0 (0.93–1.1) 1.0 (0.92–1.1)
Calendar year of ART initiation
2005 1 1 1
2006 0.95 (0.87–1.0) 0.91 (0.81–1.0) 1.0 (0.88–1.2)
2007 0.71 (0.65–0.78) 0.66 (0.59–0.74) 0.79 (0.69–0.90)
2008 0.70 (0.64–0.76) 0.64 (0.57–0.72) 0.79 (0.68–0.90)
First half 2009 0.69 (0.62–0.76) 0.64 (0.56–0.74) 0.74 (0.63–0.87)
Program characteristics
Setting
Urban - - - - 1
Rural -- -- 0.73 (0.54–0.99)
CD4 testing
On-site 0.83 (0.74–0.94) 0.86 (0.75–0.98) 0.83 (0.54–0.99)
Off-site 1 1 1 -
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when both are co-located at the same facility.
Our study has several strengths including a sex-specific analysis
and the use of routinely collected program data on a large number
of patients from several clinics in diverse settings throughout
Mozambique, each of which enhances the generalizability of our
findings. The inclusion of patient as well as clinic characteristics in
the analysis is also an added strength. However, our study also has
several limitations. Measurement error on individual-level factors
such as socio-economic status could have undermined our ability
to observe true associations with late ART initiation, and resulted
in inadequately controlled confounding by socio-economic status.
We examined the role of clinic-level characteristics that were
observed, rather than randomly assigned (i.e., experimentally), and
as such observed associations may be prone to unmeasured
confounding. We also lack information for time dependent clinic
characteristics before 2007 and, instead used data from 2007 as a
proxy. Finally, 11% of the patients had missing data on the
parameters of interest for this analysis i.e. WHO staging and
CD4+ cell count and thus were excluded from the main primary
analysis. We assessed the impact of the missing data via sensitivity
analyses with extreme assumptions and found that the findings
were similar to those from the main analysis. However, this effort
and the findings do not exclude the possibility that point estimates
could be biased as a result of missing data.
Since 2009, many programmatic changes have occurred in
Mozambique that could have contributed to reducing the problem
of late ART initiation. Mozambique started decentralizing the
health system in 2009, providing care in smaller health centers and
expanding access to HIV care and treatment throughout the
country. Also in 2009, national ART guidelines were changed to
start patients with CD4 count ,250 cells/mL independent of
clinical status, CD4 count ,350 cells/mL and WHO stage III, or
WHO stage IV independent of CD4 count. More recently, point-
of-care CD4 testing is currently being used in sites that previously
did not have CD4 machines, with the potential reduction on the
time from enrollment to ART initiation [54].
In conclusion, we observed that a large proportion of patients at
sites included in this study initiated ART in the late stages of HIV
disease. It is unclear the extent to which this is driven by distinct
upstream factors along the pathway to ART initiation – late HIV
diagnosis, late enrollment into HIV care, and late ART initiation
despite timely enrollment in care. The decreasing trend in late
ART initiation with calendar time since 2005 is encouraging but it
seems to have plateaued since 2007. Thus, upstream, structural
intervention strategies aimed at improving HIV testing coverage,
linkage to HIV care following diagnosis, retention in pre-ART
care with timely CD4 monitoring, and prompt ART initiation
following eligibility are urgently needed [4,5]. Some potential
interventions to achieve this include the use of point-of-care CD4
testing, comprehensive service packages that integrate PMTCT
services on site with ART programs and the support of community
ART groups to improve access, patient retention, and decongest
health services [39,55].The associations with late ART initiation
observed in our analyses require additional investigation, but may
represent potentially modifiable determinants of late ART
initiation in this setting. Furthermore, efforts to ensure timely
ART initiation will need to be expanded with recent changes in
WHO guidelines for ART use in resource limited settings and
recent changes in the Mozambican National guidelines that will
also expand eligibility to patients with higher CD4 cell counts [56–
60].
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